02105.HK
Laekna, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 7.19
+4.66%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
HKD 3.23B
MomentumView details →
1D Return
+4.66%
YTD Return
−47.17%
RSI (14)
57.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
HKD 3.23B
RSI (14)
57.9
MomentumView details →
1D Return
+4.66%
YTD Return
−47.17%
Similar companies
Latest newsMore news →
Laekna Healthcare initiated a Phase I clinical study of LAE118 for advanced solid tumors in China and enrolled the first subject.4d agoLaekna Inc. reported interim results for the six months ended June 2026, with revenue of RMB 150 million and a net loss narrowed to RMB 2.55 million from RMB 130 million a year earlier, with no dividend declared.10d agoLaekna (02105.HK) issued a profit alert, expecting revenue of RMB 145-155 million for the six months ending June 30, 2026, compared to zero in the prior year period, and a net loss of no more than RMB 5 million, a 96% reduction from RMB 130 million a year earlier.19d ago